Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Characterization and differentiation of equine umbilical cord-derived matrix cells.

Hoynowski SM., Fry MM., Gardner BM., Leming MT., Tucker JR., Black L.

Clinical Trial, published in Biochem Biophys Res Commun (2007) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Biochem Biophys Res Commun (2007)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
17719011
DOI
10.1016/j.bbrc.2007.07.182

Abstract (original English)

Stem cells are being evaluated in numerous human clinical trials and are commercially used in veterinary medicine to treat horses and dogs. Stem cell differentiation, homing to disease sites, growth and cytokine factor modulation, and low antigenicity contribute to their therapeutic success. Bone marrow and adipose tissue are the two most common sources of adult-derived stem cells in animals. We report on the existence of an alternative source of primitive, multipotent stem cells from the equine umbilical cord cellular matrix (Wharton's jelly). Equine umbilical cord matrix (EUCM) cells can be cultured, cryogenically preserved, and differentiated into osteo-, adipo-, chondrogenic, and neuronal cell lineages. These results identify a source of stem cells that can be non-invasively collected at birth and stored for future use in that horse or used as donor cells for treating unrelated horses.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AdipocytesAdipogenesisAlkaline PhosphataseAnimalsAnthraquinonesAzo CompoundsCell CycleCell DifferentiationCell ProliferationCells, Cultured

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.